Products
Pepinemab Biosimilar Monoclonal Antibody (SEMA4D) for Research
Pre-Made Pepinemab biosimilar, Whole mAb, Anti-SEMA4D Antibody: Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pepinemab is a humanised IgG4 monoclonal antibody against the semaphorin 4D (SEMA4D; CD100), being developed by Vaccinex for the treatment of multiple cancers, Alzheimer's disease and Huntington's disease.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-437-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Pepinemab biosimilar, Whole mAb, Anti-SEMA4D Antibody: Anti-A8/BB18/C9orf164/CD100/COLL4/GR3/M-sema-G/SEMAJ/coll-4 therapeutic antibody |
| INN Name | Pepinemab |
| Target | SEMA4D |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex |
| Conditions Approved | na |
| Conditions Active | Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer |
| Conditions Discontinued | Multiple sclerosis |
| Development Tech | na |
About target - SEMA4D
1. Protein Semaphorin-4D
2. Gene SEMA4D
3. Organism Homo sapiens (Human)
Function
Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling (PubMed:20877282).
Regulates GABAergic synapse development (By similarity).
Promotes the development of inhibitory synapses in a PLXNB1-dependent manner (By similarity).
Modulates the complexity and arborization of developing neurites in hippocampal neurons by activating PLXNB1 and interaction with PLXNB1 mediates activation of RHOA (PubMed:19788569).
Promotes the migration of cerebellar granule cells (PubMed:16055703).
Plays a role in the immune system; induces B-cells to aggregate and improves their viability (in vitro) (PubMed:8876214).
Induces endothelial cell migration through the activation of PTK2B/PYK2, SRC, and the phosphatidylinositol 3-kinase-AKT pathway (PubMed:16055703).
